Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCe...( SUNRISE Fla. July 7 /- Bioheart Inc. ...),Health

SUNRISE, Fla., July 7 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) announced today that the panel discussion on myoblast (muscle stem cell) therapy between distinguished physicians and scientists is available for playback at the following site:

http://www.bioheartinc.com/news.php#060409

After reviewing supporting pre-clinical data dating back to 1988 and clinical data from controlled studies which began in early 2000 (nearly 400 patients), a panel of experts strongly endorses moving forward to complete the final phase of clinical trials (MARVEL) to advance muscle stem cell (myoblast) therapy for treating heart failure to mainstream use with FDA approval and CMS reimbursement. The MARVEL II program aims to streamline both screening and follow-up to facilitate enrollment and to enhance safety monitoring.

During the panel discussion, Dr. Christopher O'Connor, Director Heart Center, Duke University Medical Center commented on the MARVEL program "We believe it is an endeavor worthy of strong support. It is hopeful that MARVEL II, which is one stage of the broader MARVEL program, will meet a key efficacy end point - the six-minute walk." Dr. Carl Pepine, MD, Professor of Medicine, University of Florida College of Medicine, discussed the difficulties of stem cell therapy in scar tissue. "Cells of the myoblast variety seem to be able to overcome this barrier...and this is what's so exciting about the myoblast trials that Bioheart has proposed. We are very encouraged and would like very much to continue these trials."

Highlights from the call include Dr. Doris Taylor's, Director, Center for Cardiovascular Repair, University of Minnesota, recollection of the more than 20 years of research in this field
'/>"/>